700 related articles for article (PubMed ID: 25972002)
1. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
[TBL] [Abstract][Full Text] [Related]
2. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
3. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
Smith EJ; Olson K; Haber LJ; Varghese B; Duramad P; Tustian AD; Oyejide A; Kirshner JR; Canova L; Menon J; Principio J; MacDonald D; Kantrowitz J; Papadopoulos N; Stahl N; Yancopoulos GD; Thurston G; Davis S
Sci Rep; 2015 Dec; 5():17943. PubMed ID: 26659273
[TBL] [Abstract][Full Text] [Related]
4. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
5. Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.
Ovacik AM; Li J; Lemper M; Danilenko D; Stagg N; Mathieu M; Ellerman D; Gupta V; Kalia N; Nguy T; Plaks V; David Johnson C; Wang W; Brumm J; Fine B; Junttila T; Lin K; Carter PJ; Prabhu S; Spiess C; Kamath AV
MAbs; 2019; 11(2):422-433. PubMed ID: 30550367
[TBL] [Abstract][Full Text] [Related]
6. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
7. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
8. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
Lu CY; Chen GJ; Tai PH; Yang YC; Hsu YS; Chang M; Hsu CL
Biochem Biophys Res Commun; 2016 May; 473(4):808-813. PubMed ID: 27040766
[TBL] [Abstract][Full Text] [Related]
9. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
Stanglmaier M; Faltin M; Ruf P; Bodenhausen A; Schröder P; Lindhofer H
Int J Cancer; 2008 Sep; 123(5):1181-9. PubMed ID: 18546289
[TBL] [Abstract][Full Text] [Related]
10. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma.
Brandl M; Grosse-Hovest L; Holler E; Kolb HJ; Jung G
Exp Hematol; 1999 Aug; 27(8):1264-70. PubMed ID: 10428503
[TBL] [Abstract][Full Text] [Related]
12. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
13. [Expression, identification and bioactivity characterization of an anti-CD3/anti-CD20 bispecific single-chain antibody].
Yu R; Li SC; Wu BC; Liu H; Ye LL; Chen ZL
Sheng Wu Gong Cheng Xue Bao; 2005 Mar; 21(2):289-93. PubMed ID: 16013492
[TBL] [Abstract][Full Text] [Related]
14. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
15. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
16. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
[TBL] [Abstract][Full Text] [Related]
17. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
Glorius P; Baerenwaldt A; Kellner C; Staudinger M; Dechant M; Stauch M; Beurskens FJ; Parren PW; Winkel JG; Valerius T; Humpe A; Repp R; Gramatzki M; Nimmerjahn F; Peipp M
Leukemia; 2013 Jan; 27(1):190-201. PubMed ID: 22660187
[TBL] [Abstract][Full Text] [Related]
18. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
[TBL] [Abstract][Full Text] [Related]
19. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
[TBL] [Abstract][Full Text] [Related]
20. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]